Browsing Universitätsbibliographie by Author "Grischke, Eva-Maria"

Now showing items 1-20 of 78

Next Page >>

A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer

Oza, Amit M.; Estevez-Diz, Maria; Grischke, Eva-Maria; Hall, Marcia; Marme, Frederik; Provencher, Diane; Uyar, Denise; Weberpals, Johanne I.; Wenham, Robert M.; Laing, Naomi; Tracy, Michael; Freshwater, Tomoko; Lee, Mark A.; Liu, Ji; Qiu, Jingjun; Rose, Shelonitda; Rubin, Eric H.; Moore, Kathleen (2020)
A high-risk 70-gene signature is not associated with the detection of tumor cell dissemination to the bone marrow

Walter, Vincent P.; Taran, Florin-Andrei; Wallwiener, Markus; Walter, Christina; Grischke, Eva-Maria; Wallwiener, Diethelm; Brucker, Sara Y.; Hartkopf, Andreas D. (2018)
A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)

Turner, Nicholas C.; Telli, Melinda L.; Rugo, Hope S.; Mailliez, Audrey; Ettl, Johannes; Grischke, Eva-Maria; Mina, Lida A.; Balmana, Judith; Fasching, Peter A.; Hurvitz, Sara A.; Wardley, Andrew M.; Chappey, Colombe; Hannah, Alison L.; Robson, Mark E. (2019)
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer : clinical results and biomarker analysis of GeparNuevo study

Loibl, S.; Untch, M.; Burchardi, N.; Huober, J.; Sinn, B., V; Blohmer, J-U; Grischke, E-M; Furlanetto, J.; Tesch, H.; Hanusch, C.; Engels, K.; Rezai, M.; Jackisch, C.; Schmitt, W. D.; von Minckwitz, G.; Thomalla, J.; Kuemmel, S.; Rautenberg, B.; Fasching, P. A.; Weber, K.; Rhiem, K.; Denkert, C.; Schneeweiss, A. (2019)
A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)

Bischoff, Joachim; Barinoff, Jana; Mundhenke, Christoph; Bauerschlag, Dirk O.; Costa, Serban-Dan; Herr, Daniel; Luebbe, Kristina; Marme, Frederik; Maass, Nicolai; von Minckwitz, Gunter; Grischke, Eva-Maria; Mueller, Volkmar; Schmidt, Marcus; Gerber, Bernd; Kuemmel, Sherko; Schumacher, Claudia; Krabisch, Petra; Seiler, Sabine; Thill, Marc; Nekljudova, Valentina; Loibl, Sibylle (2019)
Akzeptanz und Reliabilität eines elektronischen psychoonkologischen Screenings bei Patientinnen mit Brustkrebs: eine randomisiert-kontrollierte Studie

Schaeffeler, Norbert; Pfeiffer, Karoline; Grischke, Eva Maria; Wallwiener, Diethelm; Garbe, Claus; Zipfel, Stephan; Teufel, Martin (2013)
Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials

Furlanetto, Jenny; Marme, Frederik; Seiler, Sabine; Thode, Christian; Untch, Michael; Schmatloch, Sabine; Schneeweiss, Andreas; Bassy, Martina; Fasching, Peter A.; Strik, Dominika; Stickeler, Elmar; Schem, Christian; Karn, Thomas; Grischke, Eva-Maria; Denkert, Carsten; van Mackelenbergh, Marion; Mueller, Volkmar; Nekljudova, Valentina; Loibl, Sibylle (2021)
Chirurgische Therapie der peritonealen Metastasierung in Abhängigkeit von Tumorentität, -stadium und -charakteristik(a)

Beckert, S.; Struller, F.; Grischke, E. -M.; Glatzle, J.; Zieker, D.; Koenigsrainer, A.; Koenigsrainer, I. (2016)
Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant

Tolaney, Sara M.; Toi, Masakazu; Neven, Patrick; Sohn, Joohyuk; Grischke, Eva-Maria; Llombart-Cussac, Antonio; Soliman, Hatem; Wang, Hong; Wijayawardana, Sameera; Jansen, Valerie M.; Litchfield, Lacey M.; Sledge, George W., Jr. (2022)
CNS metastases in breast cancer patients: prognostic implications of tumor subtype

Bachmann, C.; Schmidt, S.; Staebler, A.; Fehm, T.; Fend, F.; Schittenhelm, J.; Wallwiener, D.; Grischke, E. (2015)
CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary

Bachmann, C.; Grischke, E. M.; Fehm, T.; Staebler, A.; Schittenhelm, J.; Wallwiener, D. (2013)
Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer - an Analysis of a Large University Breast Cancer Centre

Matovina, Sabine; Engler, Tobias; Volmer, Lea-Louise; Mueller, Heike; Grischke, Eva-Maria; Staebler, Annette; Hahn, Markus; Brucker, Sara Yvonne; Hartkopf, Andreas Daniel (2023)
Comparison of Neoadjuvant Nab-Paclitaxe plus Carboplatin vs Nab-Paclitaxe plus Gemcitabine in Triple-Negative Breast Cancer : Randomized WSG-ADAPT-TN Trial Results

Gluz, Oleg; Nitz, Ulrike; Liedtke, Cornelia; Christgen, Matthias; Grischke, Eva-Maria; Forstbauer, Helmut; Braun, Michael; Warm, Mathias; Hackmann, John; Uleer, Christoph; Aktas, Bahriye; Schumacher, Claudia; Bangemann, Nikola; Lindner, Christoph; Kuemmel, Sherko; Clemens, Michael; Potenberg, Jochem; Staib, Peter; Kohls, Andreas; von Schumann, Raquel; Harbeck, Nadia (2018)
Contralateral prophylactic mastectomy : Breast cancer patients from BRCA1/2 negative high risk families

Grischke, Eva-Maria (2013)
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single centre experience

Koenigsrainer, Ingmar; Horvath, Philipp; Struller, Florian; Grischke, Eva Maria; Wallwiener, Diethelm; Koenigsrainer, Alfred; Beckert, Stefan (2014)
De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial

Gluz, Oleg; Nitz, Ulrike; Kolberg-Liedtke, Cornelia; Prat, Aleix; Christgen, Matthias; Kuemmel, Sherko; Mohammadian, Mohammad Parsa; Gebauer, Daniel; Kates, Ronald; Pare, Laia; Grischke, Eva-Maria; Forstbauer, Helmut; Braun, Michael; Warm, Mathias; Hackmann, John; Uleer, Christoph; Aktas, Bahriye; Schumacher, Claudia; Wuerstlein, Rachel; Graeser, Monika; Pelz, Enrico; Jozwiak, Katarzyna; Zu Eulenburg, Christine; Kreipe, Hans Heinrich; Harbeck, Nadia (2022)
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

Nitz, Ulrike; Gluz, Oleg; Graeser, Monika; Christgen, Matthias; Kuemmel, Sherko; Grischke, Eva-Maria; Braun, Michael; Augustin, Doris; Potenberg, Jochem; Krauss, Katja; Schumacher, Claudia; Forstbauer, Helmut; Reimer, Toralf; Stefek, Andrea; Fischer, Hans Holger; Pelz, Enrico; Zu Eulenburg, Christine; Kates, Ronald; Wuerstlein, Rachel; Kreipe, Hans Heinrich; Harbeck, Nadia (2022)
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR1/HER21 Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial

Harbeck, Nadia; Nitz, Ulrike A.; Christgen, Matthias; Kuemmel, Sherko; Braun, Michael; Schumacher, Claudia; Potenberg, Jochem; Tio, Joke; Aktas, Bahriye; Forstbauer, Helmut; Grischke, Eva-Maria; Scheffen, Iris; Malter, Wolfram; von Schumann, Raquel; Just, Marianne; zu Eulenburg, Christine; Biehl, Claudia; Kolberg-Liedtke, Cornelia; Deurloo, Regula; de Haas, Sanne; Jozwiak, Katarzyna; Hauptmann, Michael; Kates, Ronald; Graeser, Monika; Wuerstlein, Rachel; Kreipe, Hans H.; Gluz, Oleg (2023)
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel

Nitz, U. A.; Gluz, O.; Christgen, M.; Grischke, E. -M; Augustin, D.; Kuemmel, S.; Braun, M.; Potenberg, J.; Kohls, A.; Krauss, K.; Stefek, A.; Schumacher, C.; Forstbauer, H.; Reimer, T.; Fischer, H.; Liedtke, C.; Wuerstlein, R.; Schumacher, J.; Kates, R.; Kreipe, H.; Harbeck, N. (2017)
De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2-and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET

Harbeck, Nadia; Gluz, Oleg; Christgen, Matthias; Kates, Ronald Ernest; Braun, Michael; Kueemmel, Sherko; Schumacher, Claudia; Potenberg, Jochem; Kraemer, Stefan; Kleine-Tebbe, Anke; Augustin, Doris; Aktas, Bahriye; Forstbauer, Helmut; Tio, Joke; von Schumann, Raquel; Liedtke, Cornelia; Grischke, Eva-Maria; Schumacher, Johannes; Wuerstlein, Rachel; Kreipe, Hans Heinrich; Nitz, Ulrike Anneliese (2017)

Now showing items 1-20 of 78

Next Page >>

Report a Publication

Help

Browse

All of DSpace
This Community

Browsing Universitätsbibliographie by Author "Grischke, Eva-Maria"

DSpace Repository

Browsing Universitätsbibliographie by Author "Grischke, Eva-Maria"

Browse

All of DSpace

This Community

My Account